Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 305, Issue 7, 2013, Pages

  Delgado, María Gabriela ^a   Gracia Sancho, Jordi ^a   Marrone, Giusi ^a   Rodríguez Vilarrupla, Aina ^a   Deulofeu, Ramon ^a   Abraldes, Juan G ^a   Bosch, Jaume ^a   García Pagán, Juan Carlos ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Endothelium; Fibrosis; Nitric oxide; ObR; Portal hypertension

Indexed keywords

CARBON TETRACHLORIDE; LEPTIN RECEPTOR; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HEMODYNAMICS; HUMAN; HUMAN CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONHUMAN; OXIDATIVE STRESS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE;

ENDOTHELIUM; FIBROSIS; NITRIC OXIDE; OBR; PORTAL HYPERTENSION;

ANIMALS; ANTIBODIES; LIVER; LIVER CIRRHOSIS; MALE; NITRIC OXIDE; PORTAL PRESSURE; RATS; RATS, WISTAR; RECEPTORS, LEPTIN; VASCULAR RESISTANCE;

EID: 84884969414     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00336.2012     Document Type: Article

References (39)

1. Benomar Y, Roy AF, Aubourg A, Djiane J, Taouis M. Cross downregulation of leptin and insulin receptor expression and signalling in a human neuronal cell line. Biochem J 388: 929-939, 2005.
2. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 15: 91-101, 2008.
3. Bosch J, Abraldes JG, Fernandez M, Garcia-Pagan JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 53: 558-567, 2010.
4. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci USA 98: 6390-6395, 2001.
5. Crespo J, Rivero M, Fabrega E, Cayon A, Amado JA, Garcia-Unzeta MT, Pons-Romero F. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 47: 1604-1610, 2002.
6. Dai K, Qi JY, Tian DY. Leptin administration exacerbates thioacetamideinduced liver fibrosis in mice. World J Gastroenterol 11: 4822-4826, 2005.
7. Elinav E, Ali M, Bruck R, Brazowski E, Phillips A, Shapira Y, Katz M, Solomon G, Halpern Z, Gertler A. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology 49: 278-286, 2009.
8. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 50: 604-620, 2009.
9. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 393: 7-20, 2006.
10. Garcia-Caldero H, Rodriguez-Vilarrupla A, Gracia-Sancho J, Divi M, Lavina B, Bosch J, Garcia-Pagan JC. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol 54: 660-665, 2010.
11. Garcia-Pagan JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 57: 458-461, 2012.
12. Gracia-Sancho J, Laviña B, Rodriguez-Vilarrupla A, Brandes RP, Fernandez M, Bosch J, Garcia-Pagan JC. Evidence against NADPH oxidase modulating hepatic vascular tone in cirrhosis. Gastroenterology 133: 959-966, 2007.
13. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, Garcia-Caldero H, Bosch J, Garcia-Pagan JC. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol 47: 220-227, 2007.
14. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, Garcia-Caldero H, Fernandez M, Bosch J, Garcia-Pagan JC. Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology 47: 1248-1256, 2008.
15. Gracia-Sancho J, Russo L, Garcia-Caldero H, Garcia-Pagan JC, Garcia-Cardena G, Bosch J. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut 60: 517-524, 2011.
16. 4-cirrhotic rats. J Hepatol 58: 240-246, 2013.
17. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28: 926-931, 1998.
18. Huang XD, Fan Y, Zhang H, Wang P, Yuan JP, Li MJ, Zhan XY. Serum leptin and soluble leptin receptor in nonalcoholic fatty liver disease. World J Gastroenterol 14: 2888-2893, 2008.
19. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, Sato N. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 34: 288-297, 2001.
20. Ikejima K, Lang T, Zhang YJ, Yamashina S, Honda H, Yoshikawa M, Hirose M, Enomoto N, Kitamura T, Takei Y, Sato N. Expression of leptin receptors in hepatic sinusoidal cells. Comp Hepatol 3, Suppl 1: S12, 2004.
21. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin receptormediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122: 1399-1410, 2002.
22. Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int 32: 199-213, 2012.
23. Knudson JD, Dincer UD, Zhang C, Swafford AN Jr, Koshida R, Picchi A, Focardi M, Dick GM, Tune JD. Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol 289: H48-H56, 2005.
24. Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 295: H1514-H1521, 2008.
25. 4 cirrhotic rats with portal hypertension. Gut 58: 118-125, 2009.
26. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, Diehl AM. Leptin regulates proinflammatory immune responses. FASEB J 12: 57-65, 1998.
27. Loureiro-Silva MR, Cadelina GW, Groszmann RJ. Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am J Physiol Gastrointest Liver Physiol 284: G567-G574, 2003.
28. Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 122: 1529-1532, 2002.
29. 4 cirrhotic rats. J Hepatol 49: 192-197, 2008.
30. McCullough AJ, Bugianesi E, Marchesini G, Kalhan SC. Genderdependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology 115: 947-953, 1998.
31. Otte C, Otte JM, Strodthoff D, Bornstein SR, Folsch UR, Monig H, Kloehn S. Expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis. Exp Clin Endocrinol Diabetes 112: 10-17, 2004.
32. Purdham DM, Rajapurohitam V, Zeidan A, Huang C, Gross GJ, Karmazyn M. A neutralizing leptin receptor antibody mitigates hypertrophy and hemodynamic dysfunction in the postinfarcted rat heart. Am J Physiol Heart Circ Physiol 295: H441-H446, 2008.
33. Reyes MR, Lazalde B, Posadas del Rio FA, Escalante B. Identification of leptin gene expression in sinusoidal endothelial rat liver cells. Endothelium 15: 121-125, 2008.
34. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 114: 344-351, 1998.
35. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2: 273-280, 2005.
36. Tartaglia LA. The leptin receptor. J Biol Chem 272: 6093-6096, 1997.
37. Testa R, Franceschini R, Giannini E, Cataldi A, Botta F, Fasoli A, Tenerelli P, Rolandi E, Barreca T. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J Hepatol 33: 33-37, 2000.
38. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, Nevens F, Sauerbruch T, Heller J. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46: 242-253, 2007.
39. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 101: 2629-2640, 2006.